🌿 Environment 6h ago · Jacob Bell

Vertex earnings get muted investor response

BioPharma Dive
BioPharma industry news
View Channel →
Source ↗ 👁 0 💬 0
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Comments (0)

Sign in to join the discussion

More Like This

In Senegal, artisanal fishing kills a surprising number of sharks and rays: study
Conservation news · 2h ago
📰
Cummins engine could fuel the RNG market; Biogas news from Vanguard, Opal
Waste Dive - Latest News · 2h ago
Ahuachapán and its restive neighbors
Earth News - Earth Science News, Earth Science, Climate Change · 3h ago
Viridian data lift prospects for thyroid eye disease drug
BioPharma Dive - Latest News · 3h ago
New research reveals repeated flooding is altering Florida freshwater resources
Earth News - Earth Science News, Earth Science, Climate Change · 3h ago
📰
AESC sells Tennessee lithium battery cell manufacturing plant to Fixx Energy
Solar Power World · 3h ago